Figure 6.
RT signatures of NOS patient relapse. Sixty NOS samples (30 relapse; 30 remission) were obtained from the Children’s Oncology Group (COG). Many of these samples were nonviable and had to be analyzed by the Repli-capture-seq S/G1 method (Figure 2), which frequently yielded a low signal-to-noise ratio. The 5 highest-quality relapse and remission samples (based on their correlation to normal B cells) were subjected to hierarchical clustering to identify RT signatures. (A) Four RT signatures distinguish patients with relapse from those in remission. Signature 1 includes all relapses, 2 includes only 3 relapses, and 3 and 4 are specific for 2 relapses. (B) RT profiles of each signature shown in panel A. (C) Ontology analysis of RT signatures shown in panel A. (D) Mutation frequencies for the genes in RT signature 1 shown in panel A. Mutation frequencies were obtained from the National Cancer Institute Genomic Data Commons Data Portal.45

RT signatures of NOS patient relapse. Sixty NOS samples (30 relapse; 30 remission) were obtained from the Children’s Oncology Group (COG). Many of these samples were nonviable and had to be analyzed by the Repli-capture-seq S/G1 method (Figure 2), which frequently yielded a low signal-to-noise ratio. The 5 highest-quality relapse and remission samples (based on their correlation to normal B cells) were subjected to hierarchical clustering to identify RT signatures. (A) Four RT signatures distinguish patients with relapse from those in remission. Signature 1 includes all relapses, 2 includes only 3 relapses, and 3 and 4 are specific for 2 relapses. (B) RT profiles of each signature shown in panel A. (C) Ontology analysis of RT signatures shown in panel A. (D) Mutation frequencies for the genes in RT signature 1 shown in panel A. Mutation frequencies were obtained from the National Cancer Institute Genomic Data Commons Data Portal.45 

Close Modal

or Create an Account

Close Modal
Close Modal